This bill establishes a Medical Psilocybin Advisory Board tasked with evaluating the benefits and drawbacks of using psilocybin for therapeutic purposes. The board will consist of various members, including medical professionals, a qualifying patient, and representatives from the veterans' affairs community and the House of Representatives. The board is responsible for assessing clinical outcomes, reviewing medical evidence, and potentially designing a program for the medical use of psilocybin. The bill also defines key terms such as "provider," "producer," and "qualifying patient," and outlines the conditions under which psilocybin may be used therapeutically, including treatment-resistant depression, PTSD, and substance use disorders.

Additionally, the bill includes provisions for the board to meet at least six times a year and mandates that it submit annual reports on its findings and recommendations starting November 1, 2028. The bill also includes a repeal clause for the advisory board's provisions, which will take effect on November 1, 2030. The implementation of the psilocybin program is contingent upon the board's determination that a regulatory framework is ready, and if not established within two years, the bill will not take effect. The Department of Health and Human Services will oversee the program, which may require additional funding and staffing to support its operations.